» Articles » PMID: 20508596

Maternal and Neonatal Factors Impacting Response to Methadone Therapy in Infants Treated for Neonatal Abstinence Syndrome

Overview
Journal J Perinatol
Date 2010 May 29
PMID 20508596
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To identify maternal and neonatal factors that impact response to methadone therapy for neonatal abstinence syndrome.

Study Design: This is a retrospective review of 128 infants that received pharmacotherapy for opiate withdrawal to identify factors associated with favorable response to methadone therapy. Maternal and neonatal data were analyzed with univariate statistics and multivariate logistic regression.

Result: Maternal methadone maintenance dose during pregnancy correlated with length of stay (P=0.009). There was an inverse correlation between the amount of mother's breast milk ingested and length of stay (β=-0.03, P=0.02). Methadone was initiated later, tapered more rapidly and was more successful as monotherapy in preterm infants. Five percent of infants were admitted to hospital again for rebound withdrawal following reduction of breast milk intake.

Conclusion: Severity of neonatal abstinence syndrome may be mitigated by titrating methadone to the lowest effective dose during pregnancy and by encouraging breast milk feeds, which should be weaned gradually.

Citing Articles

Characteristics and outcomes of neonatal opioid withdrawal syndrome in preterm infants: a retrospective cohort study in the current era.

Heyward A, Minich N, Hoffman A, Hibbs A, Zhao L, Crowley M J Perinatol. 2023; 43(7):909-915.

PMID: 37188773 DOI: 10.1038/s41372-023-01672-x.


Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline....

Ceccanti M, Blum K, Bowirrat A, Dennen C, Braverman E, Baron D J Pers Med. 2022; 12(12).

PMID: 36556236 PMC: 9782293. DOI: 10.3390/jpm12122015.


Non-pharmacological care for opioid withdrawal in newborns.

Pahl A, Young L, Buus-Frank M, Marcellus L, Soll R Cochrane Database Syst Rev. 2020; 12:CD013217.

PMID: 33348423 PMC: 8130993. DOI: 10.1002/14651858.CD013217.pub2.


Lactose-free infant formula does not change outcomes of neonatal abstinence syndrome (NAS): a randomized clinical trial.

Pandey R, Kanike N, Ibrahim M, Swarup N, Super D, Groh-Wargo S J Perinatol. 2020; 41(3):598-605.

PMID: 32868858 DOI: 10.1038/s41372-020-00797-7.


Neonatal Abstinence Syndrome Severity Index Predicts 18-Month Neurodevelopmental Outcome in Neonates Randomized to Morphine or Methadone.

Flannery T, Davis J, Czynski A, Dansereau L, Oliveira E, Camardo S J Pediatr. 2020; 227:101-107.e1.

PMID: 32805259 PMC: 7731918. DOI: 10.1016/j.jpeds.2020.08.034.